Pathophysiology of Diabetic Dyslipidemia
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
Accumulating clinical evidence has suggested serum triglyceride (TG) is a leading predictor of atherosclerotic cardiovascular disease, comparable to low-density lipoprotein (LDL)-cholesterol (C) in populations with type 2 diabetes, which exceeds the predictive power of hemoglobinA1c. Atherogenic dyslipidemia in diabetes consists of elevated serum concentrations of TG-rich lipoproteins (TRLs), a high prevalence of small dense low-density lipoprotein (LDL), and low concentrations of cholesterol-rich high-density lipoprotein (HDL)2-C. A central lipoprotein abnormality is an increase in large TG-rich very-low-density lipoprotein (VLDL)1, and other lipoprotein abnormalities are metabolically linked to increased TRLs. Insulin critically regulates serum VLDL concentrations by suppressing hepatic VLDL production and stimulating VLDL removal by activation of lipoprotein lipase. It is still debated whether hyperinsulinemia compensatory for insulin resistance is causally associated with the overproduction of VLDL. This review introduces experimental and clinical observations revealing that insulin resistance, but not hyperinsulinemia stimulates hepatic VLDL production. LDL and HDL consist of heterogeneous particles with different size and density. Cholesterol-depleted small dense LDL and cholesterol-rich HDL2 subspecies are particularly affected by insulin resistance and can be named "Metabolic LDL and HDL," respectively. We established the direct assays for quantifying small dense LDL-C and small dense HDL(HDL3)-C, respectively. Subtracting HDL3-C from HDL-C gives HDL2-C. I will explain clinical relevance of measurements of LDL and HDL subspecies determined by our assays. Diabetic kidney disease (DKD) substantially worsens plasma lipid profile thereby potentiated atherogenic risk. Finally, I briefly overview pathophysiology of dyslipidemia associated with DKD, which has not been so much taken up by other review articles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, the activation of PPARα reduces small dense LDL particles by (1) producing apo C-III-poor VLDL particles that interacts less well CETP and (2) increasing the formation of large buoyant LDL that has a high affinity to and are easily taken up by LDL receptor.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-elevated LDL cholesterol values together with higher triglycerides and lower HDL-cholesterol are common in patients with abdominal obesity, T2D, and metabolic syndrome (61, 62); these individuals often still have elevated atherogenic lipoproteins such as non-HDL (63), small LDL particles (62, 64), and VLDL (62, 64).”
From Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial (2019) · cites this paper as [64]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Cholesterol accumulation in the brain, particularly in astrocytes, contributes to this pathological process.”
From Cholesterol-driven pathological astrocytic responses in diabetes-associated cognitive impairment through astrocytic SCAP accumulation and NF-κB–C3 signaling modulation (2025) · cites this paper as [7]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Atherogenesis: a postprandial phenomenon.
Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411
Lewis, G. F., Carpentier, A., Adeli, K., & Giacca, A. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0461 · Cited by 1,333
Stampfer, M. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110036029 · Cited by 1,079
Cited by
Items 501–552 of 552
Tsay, E., Kurmaeva, D., Nuriddinov, S., Tsoy, V., Abduxalimova, S., Bozorov, S. S., Khalimova, Z., Engelsen, S. B., Magkos, F., Akbarovna, D. D., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03039-2
Understanding the Connection Between Diabetes and Cancer
Sekar, P. K. C., & Veerabathiran, R. (2026) · Springer eBooks · doi:10.1007/978-981-95-5651-9_2
Liu, B., Liu, Y., Xue, Q., Gao, F., & Qi, H. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02128-3
“Diabetic patients often have dyslipidemia, with elevated triglycerides and reduced HDL, promoting inflammation and oxidative stress that worsen bone resorption [9].”
Rahman, H. U., Zeb, A., Sikandar, N., Saleem, A., Younas, F., Ullah, I., Al‐Harrasi, A., & Rehman, N. U. (2026) · ChemistrySelect · doi:10.1002/slct.202505029
井, 淼. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.162408
Zafrah, H. A., Alqahtani, S. A., Al-Hashem, F. H., Al‐Ani, B., & Alzamil, N. M. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103425
Amssayef, A., Ajebli, M., & Eddouks, M. (2026) · Mongolian Journal of Chemistry · doi:10.5564/mjc.v27i55.4260
“Beyond carbohydrate metabolism, the insulin deficiency inherent in diabetes also disrupts lipid profiles promoting the accumulation of total cholesterol and triglycerides which elevates the risk of cardiovascular complications [26, 27].”
Redondo‐Castillejo, R., Quevedo-Torremocha, C., de la Cruz, M. L., Hernández-Martín, M., Bocanegra, A., Macho‐González, A., Cofrades, S., Álvarez, M. D., Bastida, S., López‐Oliva, M. E., et al. (2026) · Foods · doi:10.3390/foods15050878
“On the other hand, LDL cholesterol increase could be linked to a faster VLDL transformation, as VLDL tended to decrease in the same proportion, or to a delay in uptake by the liver [53,54].”
How to treat a diabetic patient with osteoporosis
Jackuliak, P., Kovářová, M., Kužma, M., Killinger, Z., & Payer, J. (2020) · Clinical Osteology · doi:10.36290/clo.2020.015
Bchir, N., Guiche, D. E., Gharbi, Y., Chehida, A. B., Zouaoui, C., & Ouertani, H. (2026) · Research Square · doi:10.21203/rs.3.rs-9244449/v1
Evaluating the Predictive Value of Endocan in Peripheral Arterial Disease
Kahraman, E., & Cetin, Ş. (2026) · European Journal of Therapeutics · doi:10.58600/eurjther2976
Mohammed, Z. M., Abdulwahid, A. B., & Mohammed, H. K. (2026) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v10i2.2827 · Cited by 2
“Furthermore, insulin resistance, diminished lipoprotein lipase activity, and compromised clearance of TG-rich particles [27] led to the accumulation of small, dense LDLs and a reduction in HDL, contributing to an atherogenic lipid profile [28].”
Zhang, X., Sun, Y., Yang, K., Guo, H., & Zhang, X. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.108935
Social, Clinical, and Behavior Determinants of Diabetes Mellitus in Indonesia
Pradipta, R. O., Efendi, F., Murti, F. A. K., Susanti, I. A., & Chong, M. C. (2026) · Public Health Nursing · doi:10.1111/phn.70123
“A normal lipid pattern of diabetes-related dyslipidemia includes raised TG and reduced high-density lipoprotein cholesterol (HDL-C) levels (Hirano 2018 ; Kalra and Raizada 2024 ).”
Ogunwale, K. A., Muhammad, B. J., Imam, U. A., Demilola, Y. H., Ikeoluwa, G. J., Oladele, B. S., Umar, A. M., Gwarzo, M. Y., Abubakar, A. S., Popoola, O. A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9556819/v1
Dyslipidemia in Pediatric Diabetes
Williams, K. M., & Ham, J. N. (2026) · Contemporary Endocrinology · doi:10.1007/978-3-032-17036-1_11
Lipid-related cardiovascular risk beyond low-density lipoprotein cholesterol
Balling, M., Hvid, K., Varbo, A., Langsted, A., Nordestgaard, B. G., & Afzal, S. (2026) · Heart · doi:10.1136/heartjnl-2025-326404
“30 32 Often, individuals with insulin resistance or the metabolic syndrome have normal levels of overall LDL cholesterol but increased numbers of sdLDL particles.”
The Prevalence of Metabolic Syndrome and Its Components among People with Type 2 Diabetes
Kamal, A. M., Begum, M., Shafin, S., Rahman, M. Z., Hossain, M. D., Islam, M., & Kibria, M. G. (2026) · TAJ Journal of Teachers Association · doi:10.70818/taj.v39i2.0683
“44, 45 The effect of this hormone in triglyceride rich lipopreotein (TRL) metabolism, and increased free fatty-acid flux secondary to insulin resistance may be the key possible reasons for this dyslipidemia among type 2 diabetes mellitus cases.”
Zhang, M., Huo, H., Yang, R., Gao, Y., Jia, Y., & Li, J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1866635 · Cited by 1
“Current views suggest that sd-LDL readily enters the arterial wall and becomes oxidized, while dysfunctional HDL loses its ability to promote reverse cholesterol transport; the two synergistically accelerate atherosclerosis progression (34).”
Study on the leukocytes infiltration and association in diabetic foot ulceration patients
Madhi, R., Majeed, M., & Hashim, N. A. (2026) · Journal of Biological Research - Bollettino della Società Italiana di Biologia Sperimentale · doi:10.4081/jbr.2026.14830
Biscetti, F., Rando, M. M., Nicolazzi, M. A., Angelini, F., Iezzi, R., Eraso, L. H., DiMuzio, P. J., Pitocco, D., Massetti, M., Gasbarrini, A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03233-w
“In T2DM, which significantly increases the risk of atherosclerosis and PAD, ApoB100 concentrations are frequently elevated, especially in patients with diabetic dyslipidemia [13].”
Brahmadande, J. S., Thangavelu, P. D., Patil, R. S., & Dhaygude, K. S. (2026) · Cureus · doi:10.7759/cureus.111951
Brahmadande, J. S., Thangavelu, P. D., Patil, R. S., & Dhaygude, K. S. (2026) · Cureus · doi:10.7759/cureus.112094
“Concurrently, diminished lipoprotein lipase activity compromises the catabolism of triglyceride-laden lipoproteins, compounding dyslipidemia [3].”
InfluentialChen, D., Fang, H., Wu, S.-G., Si, W., Wang, S. C., Liu, L.-Z., Han, Y., & Peng, X.-E. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1873940
Niu, X., Zhang, Y., Liu, Y., Zhu, Y. Z., Fang, B., Hu, C., Xu, X., Wang, R. T., Sang, Y., Zhang, Q., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1803814
Zeynettin, A., Balıkçı, O., & Demir, İ. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2901-3276
Cardiovascular health and metabolic memory
Gupta, J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44591-0.00007-2
Dong, R., Fu, J., Zhang, B., Zhang, Q., Yan, Y., & Li, G. (2026) · medRxiv · doi:10.64898/2026.08.02.26359507
Khan, F., Ullah, R., Zahoor, M., Khan, A., Haseena, Alotaibi, A., & Ullah, R. (2026) · Open Chemistry · doi:10.1515/chem-2025-0282
Attrill, E., Scarberry, S. R., Santiago, M., & Kavanagh, K. (2026) · Physiological Reports · doi:10.14814/phy2.71038
“Impaired vasodilation precedes insulin resistance in the macrovasculature and at the myocyte and adipocyte (Hirano, 2018; Konishi et al., 2017; Kubota et al., 2011; St-Pierre et al., 2010), which contributes to metabolic pathologies such as hyperinsulinemia, hypertriglyceridemia, and hyperglycemia.”
Gažarová, M., Lenártová, P., Žemberyová, J., Civáňová, L., Hačková, L., Kijovská, M., Šubová, L., & Górnicka, M. (2026) · Metabolites · doi:10.3390/metabo16080567
“It is precisely small dense LDL particles that have higher atherogenicity due to their increased oxidizability, longer circulation half-life, and greater ability to penetrate the vascular wall [1,51,52].”
Qiu, T., Cao, J., Yang, X., Luo, Y., Wang, H., & Ling, W. (2026) · Journal of Biophotonics · doi:10.1002/jbio.70344
“DLI is associated with various structural and functional liver abnormalities that affect the glycogen and lipid metabolisms [5–8].”
Lipoprotein X: artifactual lipid derangement in type 3c diabetes with obstructive liver disease
Green, D., Kumar, A. P., Byrne, B., Byrne, E., Lee, G. R., & O’Shea, P. M. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag230
“…hyperglycemic decompensation such as diabetic ketoacidosis or hyperosmolar hyperglycemic state, adipose lipolysis, increased hepatic free fatty acid flux, very low-density lipoprotein (VLDL) overproduction, and impaired lipoprotein clearance can produce a transient dyslipidemia [1].”
Bian, X., He, J., Song, C., Zhang, R., Yuan, S., Gao, G., & Dou, K. (2026) · MedComm · doi:10.1002/mco2.70919
“Dyslipidemia is more common in the T2DM population than non-T2DM population, which is a crucial reason for the increased cardiovascular risks in individuals with T2DM [ 18 ].”
Shakir, Z., Himanshu, D., Pandey, A., Siddiqui, K. U., & Ali, W. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-026-01714-y
Sankhi, M. N., Rajbhandari, S., Rayamajhi, A., Dhakal, P., Adhikari, N., & Singh, S. K. (2026) · Clinical Case Reports · doi:10.1002/ccr3.73446
“Consequently, severe hypertriglyceridemia may develop and precipitate acute pancreatitis, particularly in patients with poorly controlled diabetes [5, 6].”
Sharif, A., Mamo, J. C. L., Lam, V., Watts, G. F., Luna, G., Nesbit, M., Al‐Salami, H., Mooranian, A., & Takechi, R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1826957 · Cited by 1
“In individuals with diabetes, postprandial aberrations in lipoprotein metabolism often also result in increased production and impaired clearance of VLDL, potentially exacerbating amyloid accumulation in the brain (Hirano, 2018; van Arendonk et al., 2023).”
Muniroh, M., Hanifa, M. P., Tyastuti, D., Sopian, Y. T., & Sumantri, A. (2026) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.041.02.6347
The Relationship Between High-Fat Diet and Alzheimer’s-Like Disorders and Cognitive Dysfunction
Foroutan, T., Abedi, A., & Norouzi, M. (2026) · The Neuroscience Journal of Shefaye Khatam · doi:10.66224/shefa.14.3.100 · Cited by 1
Determinants of biochemical factors and microalbuminuria among type 2 diabetes mellitus patients
Hassan, R. M., Modher, M. N., Hussain, S. M., Rasool, B. S., Raheem, Y. S., & Hasan, A. F. (2026) · Polski Merkuriusz Lekarski · doi:10.36740/merkur202604101
Hamed, A. M., Mahrous, N. S., Soliman, S. S., Ali, L. ِ., Refaei, R. A., Beshay, O. N., Osman, A. S., Hamouda, M. E. E. M., Elmahdy, S. M., Mohamed, S. M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188184
Trivedi, R., Patel, R. C., Chaudhari, K., & Trivedi, P. (2026) · Indian Journal of Medical Biochemistry · doi:10.5005/jp-journals-10054-0353
Ho, L., Lin, P., Hsu, S. H.-J., & Su, T. (2026) · Research Square · doi:10.21203/rs.3.rs-10284743/v1
Yousef, A. I., Khalil, R. G., Abosaif, K., Alruhaimi, R. S., Alnasser, S. M., & Mahmoud, A. M. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00860-3
Zhao, Y., Su, R., Li, J., & Tuo, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1908086
“Older age, HTN, elevated FBG, increased TG, decreased VLDL-C, and decreased ApoA1 were independent predictors of GS occurrence in patients with T2DM.”
InfluentialHypertriglyceridemia: Causes, Consequences, Diagnosis, and Management
Qi, S., Chen, W., Chen, K., Yang, S., Wang, S., Ni, T., Xu, D., Mao, E., Chen, E., & Chen, Y. (2026) · MedComm · doi:10.1002/mco2.70956
“Poorly controlled diabetes is an important precipitating factor for MCS and HTG-AP [ 20, 47, 49 ].”
Nasri, H., Chitsazi, M. R., Abbasi, F., Ashouri, A. H., Rouzbahani, H., Mirzaei, S. A., Golafshan, F., Noursina, A., & Safari, F. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00884-9
Azagew, A. W., Abate, H. K., Mekonnen, C. K., Mekonnen, H. S., Tezera, Z. B., & Belay, G. J. (2024) · ASRIC Journal on Health Sciences · doi:10.68327/wlfx9040
Gao, J., Wang, J., & Wang, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1969361
“In patients with T2DM, increased circulating free fatty acids, enhanced hepatic very-low-density lipoprotein production, and impaired lipoprotein lipase-mediated clearance jointly promote RC accumulation (28, 29).”
Liang, H., Liao, Y., Yang, W., Huang, H., Gong, J., Yang, Q., Zhang, C., Chen, G., & Li, X. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107549
Chen, X., Su, W., Yang, T., Huang, J., Wu, B., Yang, Q., Jin, Y., Tang, J., Yang, P., & Yang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1978947
Metadata
- Authors
- Hirano, T.
- Affiliations
- SHOWA Medical University (JP)
- Corresponding author
- Hirano, Tsutomu
- ORCID
- Hirano, Tsutomu
- Venue
- Journal of Atherosclerosis and Thrombosis
- Publisher
- Japan Atherosclerosis Society
- Published
- 2018-09-01
- Volume
- 25
- Issue
- 9
- Pages
- 771-782
- ISSN
- 1340-3478 (ISSN-L)
- 1880-3873
- PMC
- PMC6143775
- OpenAlex
- W2820707192
- Cited by
- 552
- References
- 102
- Citations by year
- 2026: 65 · 2025: 90 · 2024: 81 · 2023: 86 · 2022: 88 · 2021: 70 · 2020: 46 · 2019: 21 · 2018: 4
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Journal of Atherosclerosis and Thrombosis (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- diabetic dyslipidemia, type 2 diabetes, triglyceride-rich lipoproteins, VLDL, small dense LDL, HDL2, HDL3 cholesterol, insulin resistance, hyperinsulinemia, lipoprotein lipase, atherosclerotic cardiovascular disease, diabetic nephropathy, plasma lipid profile
- MeSH terms
- Pioglitazone, Animals, Cholesterol, Chylomicrons, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Fatty Acids, Nonesterified, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Lipoproteins, Cholesterol, HDL, Cholesterol, LDL, Lipoproteins, VLDL, Liver, Risk, Triglycerides, Cholesterol, VLDL, Dyslipidemias, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.